Navigation Links
WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Date:11/7/2008

SHANGHAI, China, Nov. 7 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year, in vitro ADME collaboration agreement with Pfizer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

WuXi PharmaTech has enjoyed a close and cooperative relationship with Pfizer for many years, with collaborations ranging from synthetic chemistry, parallel medicinal chemistry (PMC), and ADME to bioanalytical services.

"This new agreement further strengthens our already productive relationship with Pfizer, one of our largest customers for many years, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Under the new collaboration agreement WuXi PharmaTech in partnership with Pfizer will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer.

"A high quality and flexible Asia R&D partnership network is critical to Pfizer's emerging market and Asia strategy. We want to build strong relationship with leading Contract Research Organizations such as WuXi PharmaTech to tap into the scientific talents and R&D capabilities in Asia," commented Dr. Steve Yang, Vice President and Head of Asia R&D at Pfizer.

The evaluation of ADME properties is a key step in the drug discovery and development process. WuXi will evaluate ADME properties for Pfizer compounds with the goal of providing this key information to assist Pfizer scientists to improve the pharmacokinetic properties of their compounds.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

For more information, please contact:

Sherry Shao

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-4002

Email: pr@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
2. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
3. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
4. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
5. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
6. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
7. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
8. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
10. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
11. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... a balanced, peaceful and healthy lifestyle, announced today the official launch of its much-anticipated ... frees the mind. , In development for over a year, the patented ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... and NetDimensions, a global provider of learning and performance management systems for high-consequence ... mainland China market. , “In the life sciences industry, organizations must pay much ...
(Date:1/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX ... global Phase 2b induction study in ulcerative colitis ... integrin. The aim of this randomized, double-blind, placebo-controlled, ... and efficacy of PTG-100 in approximately 240 adult ... disease. "We are very pleased ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... precedential publication its decision on the appeal filed by India-based Dishman Pharmaceutical & ... of contract against DPCL and one of its Dishman Group’s 100% wholly owned ...
Breaking Biology Technology:
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):